Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | ESR1 | P03372 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.62 |
| ▸ | SHBG | P04278 | 1/20 | 0.62 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.62 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508800 | 0.91 | CYP19A1 (0.64) | CYP19A1ESR2CYP3A4ESR1MEN1 | |
| SCHEMBL2781916 | 0.89 | MAPT (0.71) | CYP19A1ESR2CYP3A4ESR1MEN1 | |
| SCHEMBL27860085 | 0.88 | CYP19A1 (0.51) | CYP19A1ESR2CYP3A4ESR1MEN1 | |
| SCHEMBL7200859 | 0.87 | CYP1A1 (0.67) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17318042 | 0.87 | CYP1A1 (0.67) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL4758965 | 0.85 | CYP19A1 (0.61) | CYP19A1ESR2CYP3A4ESR1MEN1 | |
| SCHEMBL15544304 | 0.85 | MAPT (0.55) | CYP19A1ESR2CYP3A4ESR1MEN1 | |
| SCHEMBL773767 | 0.85 | CYP19A1 (0.66) | CYP19A1ESR2CYP3A4ESR1CYP1A1 | |
| SCHEMBL677661 | 0.84 | CYP19A1 (0.63) | CYP19A1ESR2CYP3A4TUBB4ATUBB | |
| SCHEMBL3368230 | 0.82 | CYP19A1 (0.59) | CYP19A1ESR2CYP3A4ESR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116519827-A | Method for inhibiting sesame pathogenic bacteria active ingredient generated by analyzing penicillium beijerinckii based on non-target metabonomics | 河南省农业科学院植物保护研究所 | 2023-08-01 | — | — | CN | claimed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| CN-115710592-A | Preparation process of 4',5, 7-trihydroxy flavanone | 成都欧康医药股份有限公司 | 2023-02-24 | — | — | CN | claimed |
| CN-104906195-B | Reduce the drug and health care product of Urine proteins | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 2019-01-22 | — | — | CN | claimed |
| EP-2875359-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS | Charles R Drew University of Medicine and Science (US) | 2015-05-27 | — | — | EP | claimed |
| WO-2013149258-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS | Charles Drew University of Medicine and Science (US) | 2013-10-03 | — | — | WO | claimed |
| EP-1067913-B1 | COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS | BIORESPONSE LLC (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2006024545-A1 | FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 2006-03-09 | — | — | WO | claimed |
| US-5770114-A | CONSISTS OF AN APROTIC SOLVENT, ELECTROCHROMIC ANODIC AND CATHODIC COMPOUNDS AND ONE BENZOTRIAZOLE DERIVATIVE; RADIATION RESISTANCE | GENTEX CORPORATION (US) | 1998-06-23 | — | — | US | claimed |
| US-5631038-A | COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-05-20 | — | — | US | claimed |
| US-5141745-A | Gene expression | THE LUBRIZOL CORPORATION (US) | 1992-08-25 | — | — | US | claimed |
| EP-0245931-A2 | Nodulation inducing factors | LUBRIZOL GENETICS INC. (US) | 1987-11-19 | — | — | EP | claimed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | claimed |
| US-20250114380-A1 | SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USING SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4364744-A1 | INHIBITORY AGENT FOR CELL INVASION BY VIRUS | Toyo Sugar Refining Co., Ltd. (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-116519827-A | Method for inhibiting sesame pathogenic bacteria active ingredient generated by analyzing penicillium beijerinckii based on non-target metabonomics | 河南省农业科学院植物保护研究所 | 2023-08-01 | — | — | CN | disclosed |
| EP-0065123-A1 | Hardly soluble salts of aminoglycoside antibiotics | MERCK PATENT GmbH (DE) | 1982-11-24 | — | — | EP | disclosed |
| EP-0004579-B1 | FLAVANS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-08-18 | — | — | EP | disclosed |
| EP-0051061-A2 | Novel intermediates and process for their preparation | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-05-05 | — | — | EP | disclosed |
| EP-0004579-A1 | Flavans, process for their preparation and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114380-A1 | SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USING SAME | CD38, BCL6B, DNASE1L3 | CYP19A1 3827/4885ESR2 3217/4885CYP3A4 4721/4885 |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | CYP19A1 2295/4885ESR2 4325/4885CYP3A4 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.